Claims
- 1. A compound having the formula (a) whereinA represents a heterocyclic group having 5-7 ring atoms in which 1-3 heteroatoms selected from the group O, N and S are present, R1 is hydrogen or fluoro, R2 is C1-4-alkyl, C-1-4-alkoxy or an oxo group, and p is 0, 1 or 2, Z represents nitrogen, and the dotted line represents a single bond, R3 and R4 independently are hydrogen or C1-4-alkyl, n has the value 1, R5 is halogen, hydroxy, C1-4-alkoxy or C1-4-alkyl, and q is 0, 1, 2 or 3, Y is a phenyl, furanyl or thienyl group, which groups may be unsubstituted or substituted with 1-3 substituents selected from hydroxy, halogen, C1-4-alkoxy, C1-4-alkyl, cyano, aminocarbonyl, mono- and di-C1-4-alkylaminocarbonyl, or a pharmacologically acceptable salt thereof.
- 2. A compound according to claim 1, wherein A together with the phenyl group represents a group selected from the groups having formulae (b)-(m) whereinR1 and (R2)p have the meanings given in claim 1, n is 1, and R3, R4, (R5)q, Y and Z have the meanings given in claim 1, or a pharmacologically acceptable salt thereof.
- 3. A compound according to claim 2, wherein A together with the phenyl group represents a group of the formula (b), or a group of the formula (I) which is substituted in the hetero ring with an oxo group, Y is phenyl which may be unsubstituted or substituted with 1-3 substituents selected from hydroxy, halogen, C1-4-alkoxy, C1-4-alkyl, cyano, aminocarbonyl, mono- and di-C1-4-alkylaminocarbonyl, and Z is nitrogen, or a pharmacologically acceptable salt thereof.
- 4. A compound according to claim 3, wherein R3 and R4 are hydrogen, q is O or hydroxy, methoxy or halogen, and Y is phenyl which may be unsubstituted or substituted with 1-3 substituents selected from hydroxy, halogen, C1-4-alkoxy, C1-4-alkyl, cyano, aminocarbonyl, mono- and di-C1-4-alkylaminocarbonyl, or a pharmacologically acceptable salt thereof.
- 5. A compound according to claim 4, wherein A together with the phenyl group is a group of formula (I) which is substituted in the hetero ring with an oxo group, q is O, and Y is phenyl, or a pharmacologically acceptable salt thereof.
- 6. A method for preparing a compound of the formula (a) according to claim 1, which method comprisesa) reacting a compound of the formula (n): with a compound of the formula wherein X is a leaving group; or b) reacting a compound of the formula (n) with a compound of the formula and formaldehyde; or c) reacting a compound of formula (n) with a compound of the formula and subsequently reducing the keto-group of said reaction product; or d) reacting a compound of the formula with a compound Y-Br; or e) reacting a compound of the formula with a compound of the formula B(OH)2—Y; wherein R1, R2, R3, R4, R5, Z, A, p, q, n and Y have the meanings given in claim 1.
- 7. A pharmaceutical composition, said composition comprising a pharmaceutically effective amount of at least one compound of the formula (a) according to claim 1 or a pharmacologically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- 8. A method for preparing a pharmaceutical composition for treating a CNS disorder, said method comprising combining a pharmaceutically effective amount of at least one compound of the formula (a) according to claim 1 or a pharmacologically acceptable salt thereof and a pharmaceutically acceptable carrier.
- 9. A method for treating a CNS disorder, said method comprising administering to a host in need of said treatment an effective amount of a compound of formula (a) according to claim 1 or a pharmacologically acceptable salt thereof.
- 10. A method for treating schizophrenia or a psychotic disorder, said method comprising administering to a host in need of said treatment an effective amount of a compound of formula (a) according to claim 1 or a pharmacologically acceptable salt thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
96200864 |
Mar 1996 |
EP |
|
Parent Case Info
This application is a 371 of PCT/EP97/01461 filed Mar. 20, 1997.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/EP97/01461 |
|
WO |
00 |
3/4/1999 |
3/4/1999 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO97/36893 |
10/9/1997 |
WO |
A |
US Referenced Citations (16)
Foreign Referenced Citations (3)
Number |
Date |
Country |
0650964 |
May 1995 |
EP |
WO 9413659 |
Jun 1994 |
WO |
WO 9502592 |
Jan 1995 |
WO |
Non-Patent Literature Citations (2)
Entry |
Chemical Abstracts, vol. 86, No. 5, Jan. 31, 1997, Abstract No. 29875a. |
Chemical Abstracts, vol. 121, No. 15, Oct. 10, 1994, Abstract No. 179544x. |